|
|
| Nomenclature |
|
Symbol:
|
Tg(Thy1-APPSwe,Prnp-PSEN2*N141I)152HLaoz
|
|
Name:
|
transgene insertion 152H, Laurence Ozmen
|
|
MGI ID: |
MGI:4412048 |
|
Synonyms: |
B6.152H, PS2APP |
|
Transgene:
|
Tg(Thy1-APPSwe,Prnp-PSEN2*N141I)152HLaoz
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
C57BL/6
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: A construct containing a Thy1 promoter driving expression of the human APP with the Swedish familial Alzheimer disease mutations (K670N, M671L) was co-injected with a construct containing the Prnp promoter driving the expression of human PSEN2 with the familial Alzheimer disease mutation N141I. Line 152H was used in subsequent experiments.
(J:88193, J:154969)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available |
|
| References |
|
Original: |
J:154969
Ozmen L et al.,
"Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice."
Neurodegener Dis 2009;6(1-2):29-36
|
|
All: |
5 reference(s)
|
|
Analysis Tools
